Immunocore
Immunocore Outlines Strategic Priorities on Kimmtrak and TCR Therapy Pipeline
The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.
Immunocore Launches Phase III Trial of IMC-F106C, BMS's Opdivo in Cutaneous Melanoma
BMS will supply its immune checkpoint inhibitor for testing with Immunocore's bispecific T-cell receptor candidate in patients with HLA-A*02:01-positive cancer.